Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023467 (
acute myeloid leukemia
)
35,200
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A transplantable myelogenous leukemia of an inbred Wistar/Furth rat has been established in tissue culture and cloned. The resulting transplantable leukemia line demonstrates in vitro doubling time of 20 hr, colony-forming efficiency of 5% in liquid and methylcellulos-containing medium, and a saturation density of 3.0 x 106 cells/sq cm in liquid medium. Following intraperitoneal inoculation, newborn rats developed solid tumors, ascities, and leukemia with ld50 of5 x 103 cells and mean latency of 60 days. The tumor cell morphology was consistent with that of
acute myelogenous leukemia
. Histochemical staining for myeloid enzymes revealed no evidence of myeloperoxidase, esterase, or leukocyte alkaline phosphatase; however, fluorescent antibody staining for
lysozyme
was markedly positive. Serum, urine, and ascitic fluid from rats with transplanted leukemia also contained elevated levels of
lysozyme
. There was no detectable type-CRNA virus production by this cell line after as long as 100 days in vitro. This inbred rat myelogenous leukemia should provide a useful model for studies of chemotherapy and immunoltherapy of human
acute myelogenous leukemia
.
...
PMID:Acute myelogenous leukemia of the Wistar/Furth rat: establishment of a continuous tissue culture line producing lysozyme in vitro and in vivo. 4 87
A simple cytochemical and cytobacterial method for the simultaneous demonstration of peroxidase and
lysozyme
(
muramidase
) activities in individual cells was devised. In characterization of myeloid and monocyte series, the combination of these myeloid- and monocyte-specific enzymes not only was more informative than a single enzyme but made it easier to differentiate acute myelomonocytic leukemia, with higher
lysozyme
activity, from
acute myeloid leukemia
, with higher peroxidase activity. Acute lymphocytic leukemia had no
lysozyme
or peroxidase activity.
...
PMID:Simultaneous demonstration of peroxidase and lysozyme activities in leukemic cells. 26 61
Serum
lysozyme
(
muramidase
) estimation is a simple, convenient and useful laboratory investigation. A review of the literature shows that
lysozyme
has been implicated as an aetiological factor in various disorders, and credited with being a prognostic indicator in
acute myeloid leukaemia
, but these promises have not been fulfilled. This low molecular weight protein is found in the urine of some patients with renal tubular disorders, but some workers have emphasized its importance as a causal agent in hypokalaemia of
acute myeloid leukaemia
. Research should be concentrated on
muramidase
as an expression of cell functions rather than as an aetiological factor. Hypokalaemia in
acute myeloid leukaemia
may be caused by an unidentified substance of molecular weight similar to that of
lysozyme
.
...
PMID:Lysozyme: a brief review. 26 80
Serum
lysozyme
activity was measured in samples from children with acute leukemia, malignant tumours, and in normal children. All children with acute lymphatic leukemia (ALL) had significantly reduced levels of
lysozyme
at diagnosis, and none of the children fell within the normal range. Children with ALL in complete remission had
lysozyme
levels comparable to normal chidren, while children with ALL in relapse also had pathological low levels. Children with ALL in remission and off therapy also had normal levels of
lysozyme
. Children with
acute myelogenous leukemia
had normal
lysozyme
levels, while children with monomyelocytic leukemia had substantially elevated
lysozyme
levels before treatment. Determination of serum
lysozyme
activity in children with acute leukemia is of value both for diagnosis and for evaluating the effect of therapy.
...
PMID:Serum lysozyme activity in children with acute leukemia. 27 70
The diagnostic and prognostic value of the assay of
lysozyme
in serum and urine was appreciated in 184 cases of acute leukemia. The levels were decreased in the lymphoblastic, mainly of the non B-non T type, and undifferenciated varieties, markedly raised in the monoblastic and myelo-monocytic varieties, while in the myeloblastic ones they were found normal, decreased or slightly increased, and, on the average, significantly higher in the well differenciated than in the poorly differenciated types. For a given cytological type, the level of
lysozyme
is not correlated with the frequency of the induction of complete remission. However, in the
acute myeloblastic leukemia
, a significantly higher frequency of infection during or after the induction treatment was observed in the cases presenting initially without a raised serum
lysozyme
level.
...
PMID:[Diagnostic and prognostic value of the assay of lysozyme in acute leukemia (author's transl)]. 28 35
Serum
lysozyme
activity was measured in samples from adult patients with acute leukemia, malignant tumors, and in normal adults. Twenty-eight adult patients with
acute myelogenous leukemia
(
AML
) had significantly elevated levels of
lysozyme
at diagnosis, and none of the adults fell within the normal range. Thirty-two patients with
AML
in complete remission had
lysozyme
levels comparable to normal adults, whereas patients with
AML
in relapse (eight cases) also had abnormally high levels of
lysozyme
activity. Ten patients with
AML
in remission and off therapy also had normal
lysozyme
levels. Three patients with acute lymphatic leukemia had normal
lysozyme
levels, while one child with monomyelocytic leukemia had substantially elevated
lysozyme
levels before treatment. It seems that in patients in remission and with normal blood values, the serum
lysozyme
activity is valuable for monitoring the remission.
...
PMID:The prognostic value of serum lysozyme activity in acute myelogenous leukemia. 28 68
Samples from 49 cases of myeloproliferative diseases were tested by an immunocytochemical technique for leucocyte
lysozyme
and lactoferrin. The presence of these constituents in myeloid precursors from cases of acute and chronic myeloid leukaemia reflected the degree of cellular maturation,
lysozyme
appearing (as it does in normal myeloid cells) at the stage of primary granule production (in promyelocytes), while lactoferrin wad detectable only in more mature, secondary granule-containing myeloid cells. Auer rods stained positively for
lysozyme
, in keeping with their relationship to primary granules. Monocytes from five cases of leukaemia showing predominantly monocytic differentiation were indistinguishable from normal monocytes in their staining reactions for
lysozyme
despite the presence of raised serum and urinary
lysozyme
levels. In four cases of
acute myeloid leukaemia
circulating polymorphs deficient in lactoferrin were detected: in one of these cases a similar percentage of polymorphs was
lysozyme
negative.
...
PMID:Intracellular lysozyme and lactoferrin in myeloproliferative disorders. 32 18
The classification of acute leukemia has almost invariably been based on the morphologic diagnosis into two broad categories: acute lymphocytic and
acute myeloid leukemia
. Despite the wide range of morphologic variation in both groups, strict criteria to define the subgroups have only recently been proposed. The conventional markers for B and T cells are now being applied to leukemic cells as are cytochemistry and electron microscopy, terminal deoxynucleotidyl transferase, serum
lysozyme
, and surface markers, E-rosettes, membrane immunoglobulin, antinull acute lymphocytic leukemia antiserum, and Fc and C3 receptors. The myelodysplastic syndromes may mimic acute leukemia and it is important that they be identified and treated appropriately. The high incidence with which chronic myelomonocytic leukemia terminates in acute leukemia suggests that it is a preleukemic condition, whereas refractory anemia with excess blasts and acquired idiopathic sideroblastic anemia may have long, drawn-out courses. Only a small population of patients with the latter conditions develop acute leukemia.
...
PMID:Classification of acute leukemia. 33 70
An unusual case of granulocytic sarcoma presenting in a pericardial effusion following trauma and preceding
acute myelogenous leukemia
(
AML
) by 8 months is presented. Five additional cases of granulocytic sarcoma preceding leukemia collected by the author are also tabulated. Granulocytic sarcoma in a nonautopsy population of myelogenous leukemic patients was found to be 2.9%. When presenting in an extramedullary site, especially preceding peripheral blood and bone marrow manifestations of leukemia, a misdiagnosis of histiocytic lymphoma may result. In questionable cases, other techniques including the naphthol-ASD-chloroacetate stain, touch imprints, immunoperoxidase stain for
lysozyme
, and electron microscopy should be utilized. Although only a small series, the most recent cases have shown induction/remission and survival characteristics of
AML
patients without granulocytic sarcoma.
...
PMID:Granulocytic sarcoma preceding acute leukemia: a report of six cases. 38 64
Two cases of the development of
acute myeloid leukemia
(
AML
) after treatment with alkylating agents are reported. In Case 1, melphalan and then cyclophosphamide had been given for multiple myeloma. 46 months after onset of cytostatic treatment
AML
occurred, as confirmed cytochemically and by qualitative determination of urinary
lysozyme
. In Case 2, cyclophosphamide had been given for rheumatoid arthritis. After a latency of 34 months 'smouldering leukaemia' developed with an atypical monocytic leukaemic cell population. In a third case, multiple myeloma and monocytic leukaemia developed synchronously. The causative role of melphalan and cyclophosphamide in the development of
AML
seems securely established. Despite the risk of alkylating agents in the treatment of multiple myeloma or Hodgkin's disease causing
AML
, they should not be replaced, as other drugs have been shown to be less beneficial. On the other hand, alkylating agents should be used with great caution in the treatment of non-malignant diseases.
...
PMID:[Plasmocytoma, alkylating agents, and acute myeloid leukemia (author's transl)]. 105 6
1
2
3
4
5
6
7
8
9
10
Next >>